Sarepta Therapeutics (SRPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.50-2.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SRPT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -5.2% |
| Our one-year growth estimate | diamond | -22.5% |
Growth built into the price is above our model estimate.
The price assumes 17.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SRPT — officer change
Dated 2026-06-04
The filing describes the approval of equity incentive and stock purchase plans, not a management change.
Why it matters: A drop below this level could show financial trouble. It may also affect pipeline funding.
Worry ifCash, cash equivalents, and investments are less than $800 million.
Less concerning ifCash position remains above $800 million.
Why it matters: The earnings report will show if the company is moving toward profitability. Investors will focus on revenue and loss trends.
Watch forEarnings report shows a revenue increase year over year.
Also watch forEarnings report shows a revenue decrease year over year.
Why it matters: Having a strong cash position helps develop the pipeline. It also keeps operations stable.
Supportive ifCash and equivalents reported above $900 million in Q3 2026.
Worry ifCash and equivalents drop below $850 million.
Why it matters: If revenue growth slows, it could signal trouble in the growth phase of the healthcare sector.
Worry ifRevenue growth falls below the sector median growth rate.
Less concerning ifRevenue growth remains above the sector median growth rate.
Why it matters: Updates on clinical trials for SRP-1001 and SRP-1003 will show progress in Sarepta's new therapies. Positive results could boost investor confidence.
Supportive ifPositive Phase 1/2 data reported for SRP-1001 and SRP-1003. Both showed good safety and effectiveness.
Worry ifNegative results or delays in reporting clinical data for SRP-1001 and SRP-1003.
Why it matters: Higher expenses may hurt profit goals and cash flow in 2026.
Worry ifNon-GAAP R&D and SG&A expenses reported above $900 million.
Less concerning ifNon-GAAP R&D and SG&A expenses reported below $800 million.
Why it matters: Good results may help use sirolimus with ELEVIDYS. This is for patients who cannot walk.
Supportive ifThere was an announcement of good interim results from the ENDEAVOR Cohort 8 trial.
Worry ifThere was an announcement of bad results or big delays in the ENDEAVOR Cohort 8 trial.
Why it matters: Good results would show that Sarepta's siRNA pipeline works. This would help future growth.
Supportive ifSarepta shared positive safety results from the Phase 1 trial of SRP-1005.
Worry ifNegative results or delays in the Phase 1 trial of SRP-1005.
Why it matters: Approval would make these therapies more common. This would improve their market potential.
Supportive ifFDA approval granted for sNDAs for AMONDYS 45 and VYONDYS 53.
Worry ifFDA denies or delays approval of sNDAs for AMONDYS 45 and VYONDYS 53.
Why it matters: If it drops below this level, it shows weak commercial performance. This could hurt investor confidence.
Worry ifQ3 2026 net product revenue reported below $328 million.
Less concerning ifQ3 2026 net product revenue exceeds $328 million.
Why it matters: Good results could raise confidence in Sarepta's siRNA pipeline. This may help overall growth.
Supportive ifPositive data readouts from DM1 and FSHD studies in 2H 2026.
Worry ifNegative data readouts or delays in reporting from these studies.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$229 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $623 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,922 loss on $10,000 · 39.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.